Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707579 | 1.00 | IDO1 (0.47) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5779231 | 0.83 | NT5E (0.40) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31342658 | 0.83 | NT5E (0.40) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL585377 | 0.82 | NT5E (0.46) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29589267 | 0.82 | NT5E (0.46) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2043993 | 0.79 | NT5E (0.38) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6267032 | 0.78 | KDM1A (0.50) | KDM1ANT5ENOTUMNPFFR2NPFFR1 | |
| SCHEMBL30864218 | 0.78 | KDM1A (0.50) | KDM1ANT5ENOTUMNPFFR2NPFFR1 | |
| SCHEMBL12791524 | 0.77 | PTGDR2 (0.42) | NT5ETP53MAPT | |
| SCHEMBL4209652 | 0.77 | KDM1A (0.46) | KDM1ANT5ENPFFR2NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118652170-A | New synthesis method of 5-bromo-2-chlorobenzoic acid | 宁夏法安德药业有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-115819353-B | Method for preparing 2-arylamino benzimidazole and N1-aryl-2-amino benzimidazole | 长沙晶易医药科技股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| US-12286432-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | OCUTERRA THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| CN-119731195-A | Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS | 中外制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| US-4396770-A | ANALGESICS, PSYCHOSIS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-08-02 | — | — | US | disclosed |
| EP-0020018-B1 | CHROMAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1983-06-01 | — | — | EP | disclosed |
| EP-0063799-A2 | 1-(3-(6-fluoro-1,2-benzisoxasol-3-yl)propyl)-4-hydroxy-4-phenylpiperidines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1982-11-03 | — | — | EP | disclosed |
| US-4303656-A | ANOREXIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1981-12-01 | — | — | US | disclosed |
| EP-0020018-A1 | Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-12-10 | — | — | EP | disclosed |
| US-4213989-A | 3-TRIFLUOROMETHYL GROUP ON PHENYL | ROUSSEL UCLAF (FR) | 1980-07-22 | — | — | US | disclosed |
| US-4155940-A | M-Bromo-benzotrifluorides | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-22 | — | — | US | disclosed |
| US-4076821-A | 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
| US-3947460-A | SEDATIVES-HYPNOTIC, TRANQUILIZER | SANDOZ, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | IDO1 173/4885HTR3E 1849/4885HTR3B 1404/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | IDO1 4447/4885HTR3E 4666/4885HTR3B 4507/4885 |
| US-12286432-B2 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | FFAR3, FFAR2, FFAR1 | IDO1 2603/4885HTR3E 1128/4885HTR3B 999/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | IDO1 4447/4885HTR3E 4666/4885HTR3B 4507/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | IDO1 3471/4885HTR3E 1678/4885HTR3B 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.